Leslie Citrome, MD

Esketamine Nasal Spray for the Management of Treatment Resistant Depression in Adults: What is the Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed?

Introduction: Esketamine nasal spray for management of treatment-resistant depression (TRD) was assessed using the metrics of number needed to treat (NNT), number needed to harm (NNH), an...

Jaskaran Singh , MD;

Allitia DiBernardo , MD;

Leslie Citrome , MD;

11/22/2019

Lumateperone in Pooled Late-Phase Schizophrenia Trials: Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder as monotherapy and as a...

Leslie Citrome , MD;

Eric Messamore ;

01/19/2023

Dasotraline for Treatment of Adults With Binge-Eating Disorder: Effect on Binge-related Obsessions and Compulsions

Background: In a previous study, dasotraline, a long-acting dopamine/norepinephrine reuptake inhibitor, demonstrated efficacy in the treatment of binge-eating disorder (BED). We now repor...

Leslie Citrome , MD;

Robert Goldman , PhD;

Ling Deng , PhD;

Todd Grinnell , BA;

Andrei Pikalov , MD, PhD;

Joyce Tsai , PhD;

11/22/2019

Podcasts

Outcome Measures to Consider Among Patients With Bipolar Disorder

06/20/2023

Leslie Citrome , MD;

Leslie Citrome, MD, clinical professor of psychiatry & behavioral sciences, New York Medical College, Valhalla, and founding director, Clinical Research and Evaluation Facility, Nathan S Kline Institute for Psychiatric Research, discusses why...

Leslie Citrome, MD, clinical...

06/20/2023

Veterans Health Today

Success of CME at Improving Physicians’ Knowledge of LAIs for Bipolar Disorder

Introduction: We sought to determine whether continuing medical education (CME) improves knowledge regarding bipolar disorder (BPD) and its treatment with the use of long acting injectabl...

Jovana Lubarda , PhD;

Marcello Morgan , MD, MPH;

Leslie Citrome , MD;

Roger McIntyre , MD, FRCPC;

Piyali Chatterjee-Shin ;

03/01/2019

Aripiprazole Lauroxil 2-Month Formulation for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Study

Positive and Negative Syndrome Scale (PANSS) factor scores (as described by Marder) were assessed in a post hoc analysis of data from adults with acute schizophrenia who received 25-week ...

Leslie Citrome , MD;

10/26/2023

Prevalence of Pre-existing Conditions for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies among Patients with Treatment-Resistant Depression

BACKGROUND: Comorbidities complicate clinicians' efforts to manage major depressive disorder (MDD). Pre-existing conditions and drug-drug interactions (DDI) may limit the array of safe ph...

Leslie Citrome , MD;

Laura Morrison , MPH;

John J. Sheehan , PhD, MBA, RPh;

Carmine Rossi , PhD;

Maryia Zhdanava , MA;

Oliver Lopena , PharmD;

Patrick Lefebvre , MA;

Dominic Pilon , MA;

Kruti Joshi , MPH, MD;

Swapna Karkare , MS;

10/19/2020

Efficacy of Cariprazine as Adjunctive Treatment of Major Depressive Disorder in Patients with Anxiety at Baseline: A Post Hoc Analysis of a Randomized Controlled Trial

Abstract: Background: The efficacy of adjunctive cariprazine treatment on depressive symptoms was evaluated in patients with major depressive disorder (MDD) and inadequate response to ant...

Majid Kerolous , PharmD, MPH;

Leslie Citrome , MD;

01/19/2023

Q&As

Improving Depression Symptoms and Quality of Life in Patients With Bipolar Disorder

01/25/2024

Leslie Citrome , MD;

In this Q&A, Leslie Citrome, MD, MPH, discusses why work productivity and quality of life are important considerations when treating patients with bipolar disorder, how to prevent them, and why using a wide dosing range can be beneficial.

In this Q&A, Leslie Citrome, MD,...

01/25/2024

Psych Congress Network

Lemborexant and suvorexant for treating insomnia: An indirect comparison using number needed to treat, number needed to harm, and likelihood to be helped or harmed

Introduction: Lemborexant is approved in the US for treating insomnia in adults. We evaluated the evidence-base for lemborexant and suvorexant, both dual orexin receptor antagonists (DORA...

Timothy Juday , PhD, MPA;

Norman Atkins Jr., MBA, PhD;

Feride Frech , PhD, MPH;

Leslie Citrome , MD;

Manoj Malhotra , MD;

10/08/2020